Paclitaxel plus doxorubicin in metastatic breast Ca

The Milan experience

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A pilot study conduced at the National Cancer Institute in Milan, Italy assessed the efficacy of six or eight cycles of paclitaxel (Taxol) 200 mg/m2 q3wks plus doxorubicin (Adriamycin) (60 mg/m2 q3wks) in 49 women with metastatic breast cancer who had received no prior chemotherapy. This study suggested that paclitaxel and doxorubicin should be considered for previously untreated patients who have been initially diagnosed with metastatic breast cancer and have a good performance status. The probability of complete response in these patients can be enhanced by continuing treatment with single-agent paclitaxel, and the risk of cardiotoxicity can be minimized by keeping the cumulative dose of doxorubicin below 360 mg/m2. Based on the experience in Milan, this combination is one of the most effective regimens for the treatment of women with breast cancer. Indeed, the convenience, efficacy, and tolerability of the combination justify the large trials that are currently evaluating its effects in women with operable breast cancer.

Original languageEnglish
Pages (from-to)13-15
Number of pages3
JournalOncology
Volume12
Issue number1 SUPPL.1
Publication statusPublished - 1998

Fingerprint

Paclitaxel
Doxorubicin
Breast
Breast Neoplasms
National Cancer Institute (U.S.)
Italy
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Paclitaxel plus doxorubicin in metastatic breast Ca : The Milan experience. / Gianni, Luca.

In: Oncology, Vol. 12, No. 1 SUPPL.1, 1998, p. 13-15.

Research output: Contribution to journalArticle

@article{c037f28276304276b125d713f3805729,
title = "Paclitaxel plus doxorubicin in metastatic breast Ca: The Milan experience",
abstract = "A pilot study conduced at the National Cancer Institute in Milan, Italy assessed the efficacy of six or eight cycles of paclitaxel (Taxol) 200 mg/m2 q3wks plus doxorubicin (Adriamycin) (60 mg/m2 q3wks) in 49 women with metastatic breast cancer who had received no prior chemotherapy. This study suggested that paclitaxel and doxorubicin should be considered for previously untreated patients who have been initially diagnosed with metastatic breast cancer and have a good performance status. The probability of complete response in these patients can be enhanced by continuing treatment with single-agent paclitaxel, and the risk of cardiotoxicity can be minimized by keeping the cumulative dose of doxorubicin below 360 mg/m2. Based on the experience in Milan, this combination is one of the most effective regimens for the treatment of women with breast cancer. Indeed, the convenience, efficacy, and tolerability of the combination justify the large trials that are currently evaluating its effects in women with operable breast cancer.",
author = "Luca Gianni",
year = "1998",
language = "English",
volume = "12",
pages = "13--15",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1 SUPPL.1",

}

TY - JOUR

T1 - Paclitaxel plus doxorubicin in metastatic breast Ca

T2 - The Milan experience

AU - Gianni, Luca

PY - 1998

Y1 - 1998

N2 - A pilot study conduced at the National Cancer Institute in Milan, Italy assessed the efficacy of six or eight cycles of paclitaxel (Taxol) 200 mg/m2 q3wks plus doxorubicin (Adriamycin) (60 mg/m2 q3wks) in 49 women with metastatic breast cancer who had received no prior chemotherapy. This study suggested that paclitaxel and doxorubicin should be considered for previously untreated patients who have been initially diagnosed with metastatic breast cancer and have a good performance status. The probability of complete response in these patients can be enhanced by continuing treatment with single-agent paclitaxel, and the risk of cardiotoxicity can be minimized by keeping the cumulative dose of doxorubicin below 360 mg/m2. Based on the experience in Milan, this combination is one of the most effective regimens for the treatment of women with breast cancer. Indeed, the convenience, efficacy, and tolerability of the combination justify the large trials that are currently evaluating its effects in women with operable breast cancer.

AB - A pilot study conduced at the National Cancer Institute in Milan, Italy assessed the efficacy of six or eight cycles of paclitaxel (Taxol) 200 mg/m2 q3wks plus doxorubicin (Adriamycin) (60 mg/m2 q3wks) in 49 women with metastatic breast cancer who had received no prior chemotherapy. This study suggested that paclitaxel and doxorubicin should be considered for previously untreated patients who have been initially diagnosed with metastatic breast cancer and have a good performance status. The probability of complete response in these patients can be enhanced by continuing treatment with single-agent paclitaxel, and the risk of cardiotoxicity can be minimized by keeping the cumulative dose of doxorubicin below 360 mg/m2. Based on the experience in Milan, this combination is one of the most effective regimens for the treatment of women with breast cancer. Indeed, the convenience, efficacy, and tolerability of the combination justify the large trials that are currently evaluating its effects in women with operable breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0031892696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031892696&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 13

EP - 15

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1 SUPPL.1

ER -